FOXM1 and cancer: In further analyses, FoxM1 expression was associated with poorer survival for patients with stage I/II cancer (P = 0.049) (Figure 1B, b) and for patients with stage III/IV cancer (P = 0.095) (Figure 1B, c), though the result of stage III/IV did not reach the significance.